Navigation Links
Notre Dame researcher's paper examines the biology of tumor-derived microvesicles
Date:6/21/2012

A new paper by Crislyn D'Souza-Schorey, professor of biological sciences at the University of Notre Dame, discusses the biology of tumor-derived microvesicles and their clinical application as circulating biomarkers. Microvesicles are membrane-bound sacs released by tumor cells and can be detected in the body fluids of cancer patients.

The World Health Organization (WHO) estimates that the incidence of cancer will reach approximately 9 million deaths in 2015. The rising prevalence of the disease is a major factor that drives the growth of the oncology biomarkers market. Biomarkers can be defined as any biological, chemical or physical parameter that can be utilized as an indicator of physiological or disease status. Thus, biomarkers are useful in cancer screening and detection, drug design and also to boost the effectiveness of cancer care by allowing physicians to tailor therapies for individual patientsan approach known as personalized medicine.

The new paper discusses the potential of microvesicles to present a combination of disease and tissue-specific markers that would constitute a unique, specific and identifiable biosignature for individual cancers.

"As such, it would make their sampling over time a preferred method to monitor changes to the tumor in response to treatment, especially for tissues such as the ovary or pancreas, where repeated biopsies of these organs is impractical," D'Souza-Schorey said.

Profiling of microvesicles could form the basis of personalized, targeted cancer therapies, especially as more reliable and rapid profiling technologies become available.

"For example, certain markers like HER2/neu, in addition to being elevated in breast cancer, is also increased in a relatively smaller subset of other cancers such as ovarian cancer," D'Souza-Schorey said. "This latter group of patients would benefit from existing treatment strategies that target the HER2 receptor."

The approach could be advantageous over currently used approaches of profiling whole tissue or un-fractionated body fluid particularly if circulating microvesicles indeed concentrate molecular changes that occur in the tumor, as it would increase the sensitivity of detecting critical markers of cancer progression.

"One complicating factor, though, is the presence of shed vesicles from other non-tumor cell types also in direct contact with these body fluids," D'Souza-Schorey said. "Thus, equally significant is the development of strategies to selectively capture tumor-specific markers that separate from other shed vesicle populations."

In collaboration with local oncologists, the D'Souza-Schorey laboratory is investigating the potential of microvesicles as a cancer diagnostic platform, a project under the umbrella of Notre Dame's Advanced Diagnostics and Therapeutics Initiative. The lab's research on the biology of microvesicles and their roles in tumor progression is supported by the National Cancer Institute and the Indiana Clinical and Translational Sciences Institute.

"Despite considerable strides, effort and investment in cancer biomarker research in the past decade, there are still more desirable outcomes, most especially enhanced sensitivity to enable early detection ," D'Souza-Schorey said. "An effective biomarker platform that will overcome these challenges would be paradigm shifting in cancer care."

The paper, which appears in the June 15 issue of the journal Genes and Development, was coauthored by Notre Dame graduate student James Clancy.


'/>"/>

Contact: Crislyn-D'Souza-Schorey
cdsouzas@nd.edu
574-631-3735
University of Notre Dame
Source:Eurekalert

Related medicine news :

1. Nanoparticles engineered at Notre Dame promise to improve blood cancer treatment
2. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
3. Controversial vaccine trial should never have been run in India, researchers say
4. Researchers create the first GPS for the blind
5. Researchers find gold nanoparticles capable of unzipping DNA
6. Cedars-Sinai researchers, with stem cells, advance understanding of spinal muscular atrophy
7. Researchers reveal crucial immune fighter role of the STING protein
8. MDS researchers join forces to advance patient treatments and outcomes
9. Stanford researchers discover the African cichlids noisy courtship ritual
10. Researchers determine pathway for origin of most common form of brain and spinal cord tumor
11. UCI researchers create mosquitoes incapable of transmitting malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... McKinney, Texas (PRWEB) , ... February 24, 2017 , ... ... south to The Medical Center at Craig Ranch building at 8080 State Highway 121, ... Ranch Medical District with easy access to Highway 121. , As the practice has ...
(Date:2/24/2017)... , ... February 24, 2017 , ... The California ... conference convening academic faculty engaged in or interested in palliative care education and research. ... will be held in North County San Diego on Sept. 28 and 29, 2017, ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly ... Dyer started as the Chairman of the Management Committee when IFN was originally ... including the recruitment of investor/owners and development of the business plan. He became ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to Head Over Heels’ ... February 12th. Ms. Esparza qualified into this prestigious status after winning the ... Las Vegas, Nevada. Frida is one of approximately 25 gymnasts in the nation ...
(Date:2/23/2017)... ... February 23, 2017 , ... On February ... a letter to withdraw previous guidance issued by the Obama Administration ... guidance issued in May 2016 by the Obama Administration came in response to ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017 The ... of the PhenoTest BC Kit, performed on the ... identify organisms that cause bloodstream infections and provide ... to respond to (antibiotic sensitivity). The test also ... provide this important information, which can guide antibiotic ...
(Date:2/24/2017)... 2017  Directors from Pharma To Market Pty Ltd and Ador ... resulting in the founding of Pharma To Market Pte Ltd, based ... are pleased to announce their expansion into Asia ... . The company are delighted to appoint Joelle Chia ... Singapore based entity. Joelle brings with her an ...
(Date:2/24/2017)... Medivir AB (Nasdaq Stockholm: MVIR) ... Board of Directors that will be submitted to the ... representatives of the company,s three largest shareholders at the ... accepted a seat on the Nomination Committee, and the ... Nomination Committee was as follows:  ...
Breaking Medicine Technology: